Neurogene (NGNE)
NASDAQ:NGNE
Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$27.85
-$0.86(-3.93%)
At close: 4:00 PM EST
$27.85
-$0.86(-3.93%)
Day’s Range― - ―
52-Week Range$14.65 - $37.27
Previous CloseN/A
Volume20.02K
Average Volume (3M)225.72K
Market Cap
$442.61M
Enterprise Value$332.79M
Total Cash (Recent Filing)$243.18M
Total Debt (Recent Filing)$9.13M
Price to Earnings (P/E)―
Beta3.02
Next Earnings
Aug 07, 2026EPS Estimate
-1.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.03
Shares Outstanding15,801,901
10 Day Avg. Volume272,921
30 Day Avg. Volume225,725
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-202.80
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$80.00Price Target Upside187.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-5.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthNeurogene's low leverage and sizable equity provide durable financial flexibility for a development-stage biotech. A ~0.04 debt/equity and meaningful asset base reduce refinancing risk, support continued R&D and registrational activities, and preserve optionality for partnerships or commercialization execution if clinical results are positive.
Registrational Trial ExecutionSuccessfully completing dosing in the Embolden registrational trial and overenrolling demonstrates strong operational execution and community engagement. Coupled with a clean tolerability signal across Phase 1/2 and Embolden, this materially de-risks the lead NGN-401 program and supports a clear pathway toward a BLA, a lasting structural positive if efficacy is confirmed.
Commercial Leadership & Launch ReadinessHiring an experienced rare neurology Chief Commercial Officer and aligning the board with management signals a strategic shift to commercialization preparedness. Building launch leadership early strengthens market-access planning, pricing/payer strategy and distribution readiness, lowering structural execution risk for a potential NGN-401 rollout.
Bears Say
Cash Burn & Negative Cash FlowPersistently deep negative operating and free cash flow means Neurogene is consuming cash rapidly. Sustained high burn will pressure the balance sheet over months, likely necessitating dilutive financings or partnerships, and constrains strategic flexibility for prolonged follow-up, manufacturing scale-up, or parallel development programs.
Widening Net Losses & Pre-commercial ProfileThe company's operating profile remains pre-commercial with materially widening net losses and minimal revenues. Continued large losses and negative returns on equity reduce near-term profitability visibility, extend dependency on external capital, and raise the bar for achieving sustainable margins even if lead programs reach approval.
No Recurring Revenue; Reliance On External FundingAbsence of recurring product revenue makes Neurogene structurally reliant on equity financings, collaborations and milestone payments to fund operations. This funding model increases dilution and execution risk, ties development pace to capital-market cycles, and can limit ability to consistently invest in commercial scale-up absent successful non-dilutive deals.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $14.65 and its highest was $37.27 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $442.61M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Aug 07, 2026 which is in 57 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on May 12, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.296 by -$0.094.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.43.
How many shares outstanding does Neurogene have?
Neurogene has 15,801,901 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.296. Following the earnings report the stock price went up 3.424%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.00 (187.25% Upside)
$80.00 (187.25% Upside)
Insider Transactions
Sold Shares
Worth $231.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.14%
12-Months-Change
Fundamentals
Return on Equity
-37.88%
Trailing 12-Months
Asset Growth
-16.54%
Trailing 12-Months
Company Description
Neurogene
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$80.00
▲(187.25% Upside)
Technical Analysis
Silence Therapeutics
―
Atea Pharmaceuticals
―
Elicio Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
9.37% Insiders
6.66% Mutual Funds
69.14% Other Institutional Investors
4.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---